MIM
ACRV icon

MetLife Investment Management’s Acrivon Therapeutics ACRV Stock Holding History

MetLife Investment Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,081
Closed -$64.5K – 2939
2023
Q1 		$64.5K Buy
+5,081
New +$85.3K ﹤0.01% 2686

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MetLife Investment Management's ACRV Position: Q2 2023 in Review

MetLife Investment Management sold out of Acrivon Therapeutics (ACRV) in Q2 2023, closing a stake of 5,081 shares — an estimated $64.5K sold.

MetLife Investment Management first reported a position in ACRV in Q1 2023 and held it in 1 quarter. The position peaked at $64.5K in Q1 2023. 40 funds tracked by Wall St. Rank hold ACRV as of Q2 2023.

  • MetLife Investment Management reported no remaining Acrivon Therapeutics position as of Q2 2023 after selling out during the quarter.
  • MetLife Investment Management sold 5,081 Acrivon Therapeutics shares in Q2 2023, an estimated $64.5K.
  • MetLife Investment Management first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 1 quarter.
  • MetLife Investment Management's Acrivon Therapeutics position peaked at $64.5K in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2023.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.